Evidence map›Paper›PMID 42135811›Full record

ArticleHuman genomics2026

Broad germline variant spectrum revealed by whole-exome sequencing in an underrepresented Latin American population with hereditary breast cancer.

Sarai Morales-González, Ricardo Fernández-Ramires, Hugo Carlos Bolzon Gonzalez, Alejandro E Sepúlveda-Perez, Ignacio A Silva-Mundaca, Lorena Seccia, Vinicius F Campos, Paulo Roberto Ferreira Júnior, Mateus José Dutra, Alexis Salas-Burgos and 2 more

Abstract read
In one paragraph

Article in Human genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sarai Morales-González *Department of Biochemistry and Molecular Biology, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile.
Ricardo Fernández-Ramires *Grupo Chileno de Cáncer Hereditario (GCCH), Santiago, Chile.
Hugo Carlos Bolzon GonzalezLaboratório de Genômica Estrutural, Programa de Pós-Graduação em Biotecnologia, Centro de Desenvolvimento Tecnológico, Universidade Federal de Pelotas, Pelotas, Brasil.
Alejandro E Sepúlveda-PerezCentro de Oncología de Precisión, Facultad de Medicina y Ciencias de la Salud, Universidad Mayor, Santiago, Chile.
Ignacio A Silva-MundacaCentro de Oncología de Precisión, Facultad de Medicina y Ciencias de la Salud, Universidad Mayor, Santiago, Chile.
Lorena SecciaGrupo Chileno de Cáncer Hereditario (GCCH), Santiago, Chile.
Vinicius F CamposLaboratório de Genômica Estrutural, Programa de Pós-Graduação em Biotecnologia, Centro de Desenvolvimento Tecnológico, Universidade Federal de Pelotas, Pelotas, Brasil.
Paulo Roberto Ferreira JúniorLaboratório de Genômica Estrutural, Programa de Pós-Graduação em Biotecnologia, Centro de Desenvolvimento Tecnológico, Universidade Federal de Pelotas, Pelotas, Brasil.
Mateus José DutraDepartamento de Diagnóstico Oral, Faculdade de Odontologia de Piracicaba, Universidade de Campinas, São Paulo, Brasil.
Alexis Salas-BurgosGrupo Chileno de Cáncer Hereditario (GCCH), Santiago, Chile.
Guilherme Gischkow-RucattiGrupo Chileno de Cáncer Hereditario (GCCH), Santiago, Chile.
Sebastián Morales-PisonGrupo Chileno de Cáncer Hereditario (GCCH), Santiago, Chile. sebastian.morales@umayor.cl.

Funding

Agencia Nacional de Investigación y Desarrollo SIA ANID 2023 85220068Fondo de Innovación para la Competitividad FRPD Atacama 2024 BIP 40070972Fondo Nacional de Desarrollo Científico y Tecnológico FONDECYT iniciación 2024 11240411
6 · The paper itself

Abstract

backgroundHereditary breast cancer (BC) accounts for a significant proportion of BC cases, yet germline variant interpretation remains limited in underrepresented populations such as those from Latin America. Most available genomic reference data derive from European and North American populations, constraining variant interpretations and clinical decision-making in other regions.

methodsWe performed whole-exome sequencing in 140 Chilean patients with clinically suspected hereditary BC. Germline variants were analyzed across canonical BC predisposition genes recommended by current NCCN guidelines and an extended set of additional cancer susceptibility genes. Variants were annotated and manually classified following ACMG/AMP guidelines, incorporating ClinGen gene-disease validity resources and cancer-specific CanVIG consensus recommendations.

resultsExpanded gene analysis resulted in an increased detection of pathogenic and likely pathogenic variants (~ 18% to ~ 24%) and reduced the proportion of patients with negative genetic results compared with canonical gene analysis alone. Pathogenic variants were most frequently identified in BRCA1 and BRCA2, followed by additional cancer susceptibility genes, with truncating variants representing the predominant alteration type. Exploratory analyses revealed a broad distribution of pathogenic variants across BRCA1 and BRCA2 gene regions.

conclusionsThis study provides a comprehensive overview of the germline variant spectrum in Chilean patients with suspected hereditary BC and demonstrates the added value of extended gene analysis beyond canonical predisposition genes. These findings contribute to population-specific genomic data and support efforts to improve variant interpretation and equitable implementation of genomic medicine in underrepresented populations.

Indexed as

BRCA1 ProteinBRCA2 ProteinBreast NeoplasmsGenetic Predisposition to DiseaseGerm-Line MutationAdultChileExome SequencingFemaleHumansLatin AmericaMiddle AgedSouth American PeopleBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanCancer susceptibility genesGermline variantsHereditary breast cancerLatin American populationVariant classificationWhole-exome sequencing

Identifiers

PMID42135811
PMCPMC13435756

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.